Clinical trial
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial…
NCT04619927 · Radboud University Medical Center, Other · Unknown status
Key facts
| NCT number | NCT04619927 |
|---|---|
| Title | Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease. |
| Official title | Genotype-guided Strategy for Antithrombotic Treatment Versus Conventional Clopidogrel Therapy in Peripheral Arterial Disease. |
| Acronym | GENPAD |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | ZonMw: The Netherlands Organisation for Health Research and Development Academisch Ziekenhuis Groningen Rijnstate Hospital Bernhoven Hospital Canisius-Wilhelmina Hospital |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Peripheral Arterial Disease |
| Intervention type | Drug, Genetic |
| Interventions | Direct CYP2C19 genotyping, CYP2C19 genotyping at the end of the study, Poor metabolisers, Intermediate metabolisers, Normal metabolisers and unknown metaboliser state |
| Enrollment | 2,276 |
| Start date | Mar 1, 2021 |
| Primary completion | Jun 30, 2024 |
| Completion | Dec 31, 2024 |
| First posted | Nov 6, 2020 |
| Last update posted | Apr 20, 2022 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: